Novo Nordisk Completes Patient Enrollment In A1chieve Study
Novo Nordisk has completed patients enrollment in A1chieve study, an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.
Novo Nordisk has recruited 60,000 patients in the study and is expected to release the results of the multinational study in 2011.
Novo Nordisk said that the insulin therapy study is being conducted in 28 countries across 4 continents and involves more than 3300 physicians.
Philip Home, professor of diabetes medicine at Newcastle University England and chair of the A1chieve global advisory board, said: "Multinational observational studies like A1chieve provide insights in the way current therapies are applied when it comes to varying cultural, economic and epidemiological circumstances.
"Once completed A1chieve is expected to provide locally relevant information on the effective use of modern insulins across different regimens. This information could be further useful to inform and improve the local guidelines on the management of type 2 diabetes."
Jesper H0iland, senior vice president of Novo Nordisk Region International Operations, said: "The A1chieve(R) study is another major initiative demonstrating our commitment as leaders in the field of diabetes care. Our vast experience and unmatched presence in the emerging countries has enabled us to carry out such a unique and large scale research activity of clinical importance."